Meeting
2022 ASCO Annual Meeting
Clinical outcomes of immune checkpoint inhibitor (ICI) therapy among Veterans Affairs patients with colorectal cancer and discordant dMMR/MSI-H status.
Authors
James Isaacs
Duke University, Durham, NC
James Isaacs , Aixia Guo , Vishal Vashistha , Evangelia Katsoulakis , Elizabeth Boswell , John H Strickler , Sara Ahmed , Michael J. Kelley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3534)
DOI
10.1200/JCO.2022.40.16_suppl.3534
Abstract #
3534
Poster Bd #
328
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in >28,000 colorectal tumors.
First Author: Rouba Ali-Fehmi
Poster
2022 ASCO Genitourinary Cancers Symposium
Blood-based tumor mutational burden from circulating tumor DNA and immune checkpoint inhibitors in advanced prostate cancer.
First Author: Grant Rauterkus
Poster
2024 ASCO Genitourinary Cancers Symposium
Association of HER2 expression in advanced urothelial carcinoma (aUC) and treatment outcomes with immune checkpoint inhibitors and enfortumab vedotin.
First Author: Chase Allain Shipp
Poster
2024 ASCO Gastrointestinal Cancers Symposium
POLE variant phenotypic classification to enable identification of patients with colorectal cancer (CRC) who may benefit from immune checkpoint inhibition (ICI).
First Author: Rachel Beth Keller